Free Trial
NASDAQ:RNAZ

TransCode Therapeutics Q4 2024 Earnings Report

TransCode Therapeutics logo
$11.76 -2.13 (-15.33%)
Closing price 07/29/2025 04:00 PM Eastern
Extended Trading
$11.95 +0.19 (+1.62%)
As of 07/29/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransCode Therapeutics EPS Results

Actual EPS
-$0.60
Consensus EPS
-$2.00
Beat/Miss
Beat by +$1.40
One Year Ago EPS
N/A

TransCode Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.30 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

TransCode Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

TransCode Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

TransCode Therapeutics Earnings Headlines

A $674B Industry Missed the Bigger Picture
TV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.
See More TransCode Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TransCode Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TransCode Therapeutics and other key companies, straight to your email.

About TransCode Therapeutics

TransCode Therapeutics (NASDAQ:RNAZ), Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

View TransCode Therapeutics Profile

More Earnings Resources from MarketBeat